Russell Lesley 4

What Happened
Russell Lesley, a director of Enanta Pharmaceuticals, was granted a derivative equity award on March 11, 2026 covering 20,000 shares (transaction code A). The award was reported as acquired at $0.00 (no cash paid) and is an option-style grant that becomes exercisable over time. This is a compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction date: March 11, 2026; Form 4 filed March 13, 2026 (appears timely).
• Security: Derivative (option) award for 20,000 shares; acquisition price reported $0.00.
• Shares owned after transaction: Not specified in the filing.
• Footnote: The option vests in substantially equal monthly installments over one year beginning March 11, 2026, with the final installment vesting no later than the trading day before the 2027 annual meeting.
• No 10b5-1 plan, tax-withholding sale, or late‑filing indication noted in the provided details.

Context
This was a standard equity compensation grant to a board member. Such awards are common for aligning directors’ interests with shareholders and do not by themselves signal insider buying or selling activity. The grant becomes exercisable monthly over a year per the footnote; it’s a derivative award (option) rather than an immediate stock purchase.